GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Cyclically Adjusted PS Ratio

Corcept Therapeutics (Corcept Therapeutics) Cyclically Adjusted PS Ratio : 11.18 (As of May. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-05-16), Corcept Therapeutics's current share price is $27.61. Corcept Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $2.47. Corcept Therapeutics's Cyclically Adjusted PS Ratio for today is 11.18.

The historical rank and industry rank for Corcept Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

CORT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.18   Med: 22.35   Max: 82.4
Current: 11.25

During the past years, Corcept Therapeutics's highest Cyclically Adjusted PS Ratio was 82.40. The lowest was 9.18. And the median was 22.35.

CORT's Cyclically Adjusted PS Ratio is ranked worse than
71.09% of 512 companies
in the Biotechnology industry
Industry Median: 5.535 vs CORT: 11.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Corcept Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.336. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.47 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Corcept Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Corcept Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Cyclically Adjusted PS Ratio Chart

Corcept Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.39 21.72 13.54 10.90 13.85

Corcept Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.92 10.55 12.18 13.85 10.18

Competitive Comparison of Corcept Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Corcept Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Cyclically Adjusted PS Ratio falls into.



Corcept Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Corcept Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=27.61/2.47
=11.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Corcept Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.336/131.7762*131.7762
=1.336

Current CPI (Mar. 2024) = 131.7762.

Corcept Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.058 100.560 0.076
201409 0.072 100.428 0.094
201412 0.089 99.070 0.118
201503 0.099 99.621 0.131
201506 0.111 100.684 0.145
201509 0.122 100.392 0.160
201512 0.137 99.792 0.181
201603 0.146 100.470 0.191
201606 0.171 101.688 0.222
201609 0.187 101.861 0.242
201612 0.200 101.863 0.259
201703 0.228 102.862 0.292
201706 0.289 103.349 0.368
201709 0.340 104.136 0.430
201712 0.417 104.011 0.528
201803 0.451 105.290 0.564
201806 0.489 106.317 0.606
201809 0.511 106.507 0.632
201812 0.534 105.998 0.664
201903 0.523 107.251 0.643
201906 0.593 108.070 0.723
201909 0.669 108.329 0.814
201912 0.716 108.420 0.870
202003 0.763 108.902 0.923
202006 0.719 108.767 0.871
202009 0.694 109.815 0.833
202012 0.676 109.897 0.811
202103 0.613 111.754 0.723
202106 0.723 114.631 0.831
202109 0.768 115.734 0.874
202112 0.808 117.630 0.905
202203 0.814 121.301 0.884
202206 0.896 125.017 0.944
202209 0.872 125.227 0.918
202212 0.885 125.222 0.931
202303 0.915 127.348 0.947
202306 1.074 128.729 1.099
202309 1.113 129.860 1.129
202312 1.222 129.419 1.244
202403 1.336 131.776 1.336

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corcept Therapeutics  (NAS:CORT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Corcept Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (Corcept Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Executives
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025

Corcept Therapeutics (Corcept Therapeutics) Headlines

From GuruFocus

Corcept Therapeutics Provides Miricorilant Clinical Development Update

By Value_Insider Value_Insider 12-08-2022

Corcept Therapeutics Initiates CATALYST Clinical Trial

By sperokesalga sperokesalga 03-28-2023